• Publications
  • Influence
Marked decline in serum concentrations of adrenal C19 sex steroid precursors and conjugated androgen metabolites during aging.
A marked decline in circulating adrenal C19 steroids and their resulting androgen metabolites takes place between the age groups of 20- to 30-yr olds and 50- to 60-yr-olds, with smaller changes observed after the age of 60 yr, suggesting a parallel decrease in the total androgen pool with age. Expand
Screening decreases prostate cancer mortality: 11‐year follow‐up of the 1988 Quebec prospective randomized controlled trial
This clinical trial is aimed at evaluating the impact of prostate cancer screening on cancer‐specific mortality in men newly diagnosed with prostate cancer. Expand
Changes in serum concentrations of conjugated and unconjugated steroids in 40- to 80-year-old men.
The present study suggests that in contrast to the marked decline in activity of steroidogenic enzymes in the adrenals and the small decrease in the testis, the activity of the steroid-converting enzymes present in peripheral tissues does not decrease during aging. Expand
Effect of 12-month dehydroepiandrosterone replacement therapy on bone, vagina, and endometrium in postmenopausal women.
The stimulatory effect on bone mineral density accompanied by an increase in serum osteocalcin, a marker of bone formation, suggests stimulation ofBone formation by the androgenic action of DHEA, a finding of particular interest for both the prevention and treatment of osteoporosis. Expand
Beneficial effect of combination hormonal therapy administered prior and following external beam radiation therapy in localized prostate cancer.
The preliminary analysis of this clinical trial indicates that patients treated with radiation therapy alone show a significantly higher rate of positive biopsies at 12 and 24 months after the end of radiation therapy as compared with those treated with total antiandrogen blockade (TAB) and radiation therapy. Expand
Physiological changes in dehydroepiandrosterone are not reflected by serum levels of active androgens and estrogens but of their metabolites: intracrinology.
The present study demonstrates that the serum concentrations of testosterone, DHT, E1, and E2 are poor indicators of total androgenic and estrogenic activity, and the esterified metabolites of DHT appear as reliable markers of the total androgens pool. Expand
Serum prostate specific antigen as pre-screening test for prostate cancer.
Simple measurement of serum PSA can be used efficiently as a pre-screening test for prostate cancer in the general population to identify, at a low cost, the subpopulation of men at a much greater risk of having prostate cancer, and who should then be submitted to the more elaborate and expensive diagnostic procedures. Expand
Screening decreases prostate cancer death: First analysis of the 1988 Quebec Prospective Randomized Controlled Trial
The 46,193 men aged 45 to 80 years registered in the electoral roll of Quebec City and its Metropolitan area were randomized in November 1988 between screening and no screening in a study aimed ofExpand
Incidence of liver toxicity associated with the use of flutamide in prostate cancer patients.
The cases reported so far indicate that the incidence of flutamide-induced liver toxicity is very low, and serial blood aminotransferase measurements are recommended at 2 and 4 weeks of treatment in order to detect early signs of possible flutamia-induced hepatic injury, thus avoiding the low potential risk of clinically significant liver toxicity. Expand
Comparison of residual C-19 steroids in plasma and prostatic tissue of human, rat and guinea pig after castration: unique importance of extratesticular androgens in men.
The plasma levels of DHEAS, DHEA, delta 4-dione are markedly different between men and both animal models used and measurements of prostatic levels of androgens suggest that the high plasma Levels of these steroids are likely responsible for the presence of important amounts of DHT in human prostate after castration. Expand